• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Csl Ltd ADR (OP: CSLLY )

    93.50 -1.44 (-1.52%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Csl Ltd ADR

    Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
    Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial 
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    CSL Joins Accumulus Synergy to Drive Industry Change
    Following the launch of Accumulus Synergy’s innovative cloud-based information exchange platform, CSL joins the nonprofit industry association 
    From Accumulus Synergy
    Via GlobeNewswire
    Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
    From CSL Behring
    Via GlobeNewswire
    Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
    From Arcturus Therapeutics
    Via Business Wire
    ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
    Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
    Via MarketBeat
    Exposures Product Safety
    Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
    From Arcturus Therapeutics
    Via Business Wire
    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
    From Arcturus Therapeutics
    Via Business Wire
    Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
    Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in... 
    From Cara Therapeutics, Inc.
    Via GlobeNewswire
    OTC Markets Group Welcomes CSL Limited to OTCQX
    From OTC Markets
    Via GlobeNewswire
    Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
    From Amarin Corporation plc
    Via GlobeNewswire
    Why CSL Ltd Stock Could Be Worth a Look
    FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
    Via MarketBeat
    Exposures Product Safety
    Finalization of Vifor Pharma acquisition
    From Vifor Pharma AG
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.